Literature DB >> 9164948

Sequential development of structural and functional alterations in T cells from tumor-bearing mice.

M R Correa1, A C Ochoa, P Ghosh, H Mizoguchi, L Harvey, D L Longo.   

Abstract

The TCR alpha beta or -gamma delta chains bind the peptide ligand, whereas the associated CD3 delta epsilon gamma and TCR zeta subunits couple the TCR to intracellular signal transduction components. Recently, several groups have described marked alterations in signal transduction elements in T cells from cancer patients or in mice bearing tumor for a few weeks (>26 days). The sequence in which these alterations develop is unknown. The aim of this study was to explore the kinetics of the development of alterations in signal transduction molecules (TCR zeta chain, NF kappaB family proteins, and tyrosine kinase p56(lck)) in mice bearing MC38 colon adenocarcinoma. The results demonstrate that alterations in NF kappaB family proteins, specifically the failure of p65 translocation to the nucleus, occur earlier and more frequently than the decrease in zeta-chain. These defects are paralleled by an impaired ability to produce Th1 cytokines (IL-2 and IFN-gamma). These initial changes are followed by the eventual loss of TCR zeta chain and p56(lck) and a marked decrease in cytotoxic function. An increased rate of lysosomal degradation is one of the mechanisms responsible for the loss of zeta-chain.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9164948

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

1.  NKG2D initiates caspase-mediated CD3zeta degradation and lymphocyte receptor impairments associated with human cancer and autoimmune disease.

Authors:  Nobuyoshi Hanaoka; Bana Jabri; Zhenpeng Dai; Cezary Ciszewski; Anne M Stevens; Cassian Yee; Hideki Nakakuma; Thomas Spies; Veronika Groh
Journal:  J Immunol       Date:  2010-10-06       Impact factor: 5.422

2.  Cutting Edge: Engineering Active IKKβ in T Cells Drives Tumor Rejection.

Authors:  César Evaristo; Stefani Spranger; Sarah E Barnes; Michelle L Miller; Luciana L Molinero; Frederick L Locke; Thomas F Gajewski; Maria-Luisa Alegre
Journal:  J Immunol       Date:  2016-02-22       Impact factor: 5.422

3.  Human melanoma cells do not express Fas (Apo-1/CD95) ligand.

Authors:  D B Chappell; T Z Zaks; S A Rosenberg; N P Restifo
Journal:  Cancer Res       Date:  1999-01-01       Impact factor: 12.701

4.  CD3 hyporesponsiveness and in vitro apoptosis are features of T cells from both malignant and nonmalignant secondary lymphoid organs.

Authors:  S Agrawal; J Marquet; M H Delfau-Larue; C Copie-Bergman; H Jouault; F Reyes; A Bensussan; J P Farcet
Journal:  J Clin Invest       Date:  1998-11-01       Impact factor: 14.808

5.  Failure of tumor-reactive lymph node cells to kill tumor in the presence of immune-suppressive CD34+ cells can be overcome with vitamin D3 treatment to diminish CD34+ cell levels.

Authors:  K Wiers; M A Wright; K Vellody; M R Young
Journal:  Clin Exp Metastasis       Date:  1998-04       Impact factor: 5.150

6.  Mechanism of T cell tolerance induced by myeloid-derived suppressor cells.

Authors:  Srinivas Nagaraj; Adam G Schrum; Hyun-Il Cho; Esteban Celis; Dmitry I Gabrilovich
Journal:  J Immunol       Date:  2010-02-08       Impact factor: 5.422

7.  Tumors induce the formation of suppressor endothelial cells in vivo.

Authors:  Jennifer Konopa Mulligan; M Rita I Young
Journal:  Cancer Immunol Immunother       Date:  2010-02       Impact factor: 6.968

8.  Phenotype, functions and fate of adoptively transferred tumor draining lymphocytes activated ex vivo in mice with an aggressive weakly immunogenic mammary carcinoma.

Authors:  Catriona H T Miller; Laura Graham; Harry D Bear
Journal:  BMC Immunol       Date:  2010-11-04       Impact factor: 3.615

9.  Covert operations: cancer's many subversive tactics in overcoming host defenses.

Authors:  Dan L Longo
Journal:  Trans Am Clin Climatol Assoc       Date:  2013

Review 10.  Signaling defects in anti-tumor T cells.

Authors:  Alan B Frey; Ngozi Monu
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.